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Abstract
Background: Canavan disease is a devastating autosomal recessive leukodystrophy leading to spongiform
degeneration of the white matter. There is no cure or treatment for Canavan disease, and disease progression is
poorly understood.
Results: We report a new presentation of a patient found to have Canavan disease; brain magnetic resonance
imaging (MRI) revealed white matter cytotoxic edema, indicative of an acute active destructive process. We
performed a comprehensive review of published cases of Canavan disease reporting brain MRI findings, and found
that cytotoxic brain edema is frequently reported in early Canavan disease.
Conclusions: Our results and the literature review support the notion of an acute phase in Canavan disease
progression. These findings suggest that there is a window available for therapeutic intervention and support the
need for early identification of patients with Canavan disease.
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Background
Canavan disease is a devastating autosomal recessive
leukodystrophy leading to spongiform degeneration of
the white matter [1]. Deficient aspartoacylase activity
from mutations in ASPA lead to accumulation of N-
acetylaspartic acid (NAA) in the brain, myelin loss [2, 3],
and NAA acidemia with elevated levels of NAA present
in cerebrospinal fluid, blood, and urine [4]. Patients with
Canavan disease typically present with developmental
delay, focal neurological signs, macrocephaly, and even
neurological deterioration in the first year of life [5]. There
is no cure or treatment for Canavan disease, and disease
progression is poorly understood. Magnetic resonance im-
aging (MRI) of the brain can be diagnostic, based on the
presence of diffuse symmetric T2 hyperintense signal in
the cortical white matter and basal ganglia with an accom-
panying elevated NAA peak seen on magnetic resonance
spectroscopy (MRS) [6, 7].
We report a patient presenting with brain MRI white
matter cytotoxic edema, indicative of an acute active
destructive process, who was found to have Canavan
disease. Review of the literature suggests that cytotoxic
edema is a common finding in early Canavan disease,
and supports the potential for a therapeutic window of
intervention.
Methods
A ten-week old boy presented with episodes of right
pendular horizontal nystagmus lasting two to three
seconds. He had been born full term following an uncom-
plicated pregnancy to nonconsanguineous Caucasian par-
ents. Vitals and general physical exam were unremarkable
and head circumference was at the 63rd percentile. Neuro-
logic examination was notable for a lack of visual tracking,
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central hypotonia, limb hyperreflexia, and choreiform limb
movements.
We conducted PubMed searches for the terms “Cana-
van” and “MRI” or “Canavan” and “diffusion” to identify
potential relevant publications. Identified publications
were reviewed for relevant cases involving cytotoxic edema
on brain MRI and data were extracted (STM and JLB).
Results
Brain MRI performed at presentation revealed extensive
diffusion restriction symmetrically in the subcortical
white matter of both cerebral hemispheres, extending in-
feriorly in the corticospinal tracts and into the brainstem
including the dorsal and ventral pons, with T2 hyperinten-
sity and T1 hypointensity of the white matter (Fig. 1 a-h).
Single voxel magnetic resonance spectroscopy (MRS) of
the white matter of the posterior left hemisphere demon-
strated an elevated peak at 2.02 ppm indicating increased
NAA (Fig. 1i). The short echo-time (TE) spectrum N-
acetylaspartic acid/creatine (NAA/CR) ratio was elevated
at 2.45 (normal for age 1.71) [8]. Urine organic acids had
elevated NAA excretion (>750 mmol NAA/mol creatin-
ine), consistent with Canavan disease. Sequencing of the
ASPA gene demonstrated a homozygous p.Ala305Glu
(c.914 C >A) point mutation confirming the diagnosis.
To determine if cytotoxic edema with diffusion restric-
tion was a common pathophysiological feature of Canavan
disease we reviewed cases using PubMed. We identified
81 potentially relevant publications; including our own re-
port there were 13 Canavan disease patients in whom
cytotoxic edema and diffusion restriction was reported
(Table 1). The median age of presentation was 12 months
(average age 32 months; range 0.8 to 171 months). For the
eleven patients in whom gender was reported, ten were
male. Of nine cases reporting head size, one patient was
microcephalic, five were normocephalic, and four were
macrocephalic.
Discussion
We found that cytotoxic edema with corresponding diffu-
sion restriction on brain MRI is more commonly observed
in Canavan disease than previously appreciated. Besides
our own case, we identified twelve other published reports
of Canavan disease with diffusion restriction. It is difficult
to assess the frequency of diffusion restriction in Canavan
Fig. 1 a-h Axial MRIs. a DWI shows hyperintensity in the internal
capsule and subcortical white matter; B) ADC demonstrates
corresponding hypointensities; c T2 FLAIR image; d T1 image.
e DWI with hyperintensities in the subcortical white matter;
f Corresponding ADC hypointensities; g T2 image; d T1 image.
i Single voxel MRS demonstrates increased NAA (arrow, peak at
2.02 ppm; choline, asterisk, 3.2 ppm; creatine, arrowhead, 3 ppm);
inset shows area of analysis in the posterior left hemisphere
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disease, since many published cases of Canavan disease do
not include MRI reports, and diffusion restriction may
only be present early in the disease course. Because diffu-
sion restriction has not been considered as a presenting
feature of Canavan disease, patients have sometimes first
been evaluated for other non-leukodystrophy causes, e.g.,
stroke [9]. Further, it is increasing recognized that there is
a broader phenotypic variability [5] with milder clinical
courses in some patients [10] and even absence of features
consider pathognomonic; for example the absence of
macrocephaly [11].
Disease pathology in Canavan is related to NAA accu-
mulation [2, 3]. In turn, the degree of ASPA impairment
from different mutations correlates with clinical disease
severity [12]. While NAA accumulation appears respon-
sible for the spongiform myelin loss, NAA also has im-
portant roles in normal CNS function. Acetate derived
from catabolism of NAA by ASPA is utilized by oligo-
dendrocytes to synthesize the lipid component of the
myelin sheath [1]. The ASPA enzyme is expressed widely
in the body, but NAA is found exclusively in the brain
[13, 14]. It has been shown that during neuronal devel-
opment increased myelination correlates with increased
ASPA activity [15]. NAA also appears to function as a
molecular water pump in neurons [16]. These roles of
NAA may contribute to the histopathology of Canavan
disease, which includes astroglial swelling and intramyeli-
nic edema [17, 18], and which may in turn be correlated
with alterations in anisotropy and the diffusion coefficient
seen on MRI. Diffuse brain edema with an increase in
cerebral water content is also seen in other disorders (for
example Congenital Muscular Dystrophy with Merosin
Deficiency [19]), but without NAA accumulation, raising
the possibility that NAA accumulation is not the primary
cause of the edema.
Interest in improved understanding of the pathology
and the early diagnosis of Canavan disease has arisen in
part because of the potential for new treatments [20].
Gene therapy replacement of ASPA has been used success-
fully in a rodent Canavan model and appears safe in
humans [21, 22]. Pharmacologic strategies to target osmotic
pressure in Canavan also appear promising [23]. However,
screening for Canavan disease is only recommended for
high-risk groups [5], although advances in next-generation
sequencing and in liquid chromatography-tandem mass
spectrometry (e.g., [4]), suggest increased potential for
broader newborn screening. The presence of cytotoxic
edema, indicated by an increase in diffusion restriction [24],
suggests that there is an acute neurotoxic process occur-
ring. Because the diffusion restriction is abnormal for only
approximately a week or less after damage, the presence of
diffusion restriction shows that at least some of the disease
pathology in Canavan disease is occurring post-natally. If a
therapy was available it could be instituted as soon as the
diagnosis was made, even if some disease progression had
already occurred.
Table 1 Canavan disease patients reported with cytotoxic edema
Reference Gender Age (months) Seizures Delay Hypotonia Spasticity Macrocephaly Affected brain structures Abnormal DWI brain structures
a m 17 na na na na na sc sc
b m 15 + + – + + bs, cer, p, t, gp bs, cer, p, t, gp
c m 72 na na na na na sc, cc sc, cc
c m 12 na na na na na sc, ppv sc
d m 11 + + – – + sc, bs sc, bs
e m 10 – + + – + sc, gp, t sc, gp, t
f na 17 + + – + – sc, gp, t, cer sc, gp, t, cer
f na 171 – + – + microcephaly sc sc
g m 0.8 na na na na + sc, bs, t, cer, bg sc, bs, t, bg
h m 7 na na na na na sc sc
i f 84 – + – – – bg, sc bg, sc
j m 4 + – – – – bg, sc bg, sc
k m 2 – – – – – bs, sc, intcap bs, sc, intcap
References: a, Engelbrecht V, Scherer A, Rassek M et al. Diffusion-weighted MR imaging in the brain in children: findings in the normal brain and in the brain with
white matter diseases. Radiology. 2002;222(2):410–8; b, [6]; c, Patay Z. Diffusion-weighted MR imaging in leukodystrophies. Eur Radiol. 2005;15(11):2284–303; d,
Srikanth SG, Chandrashekar HS, Nagarajan K et al. Restricted diffusion in Canavan disease. Childs Nerv Syst. 2007;23(4):465–8.; e, Unalp A, Altiok E, Uran N et al.
Novel mutation of aspartoacylase gene in a Turkish patient with Canavan disease. J Trop Pediatr. 2008;54(3):208–10.; f, Cakmakci H, Pekcevik Y, Yis U et al. Diagnostic
value of proton MR spectroscopy and diffusion-weighted MR imaging in childhood inherited neurometabolic brain diseases and review of the literature. Eur J Radiol.
2010;74(3):e161-71; g, Rodrigues K, Grant PE. Diffusion-weighted imaging in neonates. Neuroimaging Clin N Am. 2011;21(1):127–51, viii; h, Perlman SJ, Mar S.
Leukodystrophies. Adv Exp Med Biol. 2012;724:154–71; i, Nguyen HV, Ishak GE. Canavan disease – unusual imaging features in a child with mild clinical
presentation. Pediatr Radiol. 2014;45:457–60.; j, [9]; k, this report
Abbreviations: m male, f female, na not available, intcap internal capsule, bs brain stem, cc corpus callosum, bg basal ganglia, cer cerebellum, p pons, t thalamus, gp
globus pallidus, ppv parietal periventricular, sc subcortical white matter
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Conclusions
Our case and review of the literature show that cytotoxic
edema with diffusion restriction on brain MRI is often
observed in infant-onset Canavan disease, and if an in-
fant presents with diffusion restriction Canavan disease
should be considered in the differential. Our results sup-
port the notion of an acute phase in disease progression.
Together with evidence that NAA levels are related to
myelin degeneration [2, 3], that NAA levels rise during
the first year of life in Canavan disease [25], and the possi-
bility for potential treatments [20, 22, 23], these findings
suggest that there is a window available for therapeutic
intervention and support the need for early identification




The authors state they have no funding related to this project.
Availability of data and materials
Not applicable.
Authors’ contributions
STM and JLB analyzed and interpreted the patient data and other cases. All
authors contributed to interepretation of the data, and read and approved
the final manuscript.
Competing interests
The authors state that they have no competing interests.
Consent for publication
Consent for publication was provided by the parents, whom we thank for
the help.
Ethics approval and consent to participate
The Institutional Review Boards of the University of Utah and Intermountain
Healthcare (IH) approved this study.
Data sharing and supplemental materials
Data sharing not applicable to this article as no datasets were generated or
analyzed during the current study. There are no supplemental materials
associated with this article.
Author details
1College of Osteopathic Medicine, Touro University Nevada, Henderson, NV,
USA. 2Division of Pediatric Neurology, University of Utah School of Medicine,
Salt Lake City, UT, USA. 3Division of Medical Genetics, Department of
Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA.
4Department of Pediatrics, University of Utah School of Medicine, 295
Chipeta Way/Williams Building, 84108 Salt Lake City, UT, USA.
Received: 13 September 2016 Accepted: 29 November 2016
References
1. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. N-Acetylaspartate
in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol.
2007;81:89–131.
2. Maier H, Wang-Eckhardt L, Hartmann D, Gieselmann V, Eckhardt M. N-
Acetylaspartate synthase deficiency corrects the myelin phenotype in a
canavan disease mouse model but does not affect survival time. J Neurosci.
2015;35:14501–16.
3. Guo F, Bannerman P, Mills Ko E, Miers L, Xu J, Burns T, Li S, Freeman E,
McDonough JA, Pleasure D. Ablating N-acetylaspartate prevents
leukodystrophy in a Canavan disease model. Ann Neurol. 2015;77:884–8.
4. Al-Dirbashi OY, Rashed MS, Al-Qahtani K, Al-Mokhadab MA, Kurdi W, Al-
Sayed MA. A quantification of N-acetylaspartic acid in urine by LC-MS/MS
for the diagnosis of Canavan disease. J Inherit Metab Dis. 2007;30:612.
5. Matalon R, Michals-Matalon K. Canavan disease. 1999 Sep 16 [updated 2011
Aug 11]. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A,
Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors.
GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle;
1993–2016. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1234/.
Accessed May 15, 2016.
6. Sener RN. Canavan disease: diffusion magnetic resonance imaging findings.
J Comput Assist Tomogr. 2003;27:30–3.
7. Barkovich AJ, Patay Z. Metabolic, toxic, and inflammatory brain disorders. In:
Barkovich AJ, Raybaud C, editors. Pediatric Neuroimaging. 5th ed.
Philadelphia: Wolters Kluwer Health; 2012. p. 81–239.
8. Pouwels PJW, Brockmann K, Kruse B, Wilken B, Wick M, Hanefeld F, Frahm J.
Regional age dependence of human brain metabolites from infancy to
adulthood as detected by quantitative localized proton MRS. Pediatr Res.
1999;46:474.
9. Delaney KE, Kralik SF, Hainline BE, Golomb MR. An atypical case of canavan
disease with stroke-like presentation. Pediatr Neurol. 2015;52:218–21.
10. Sarret C, Boespflug-Tanguy O, Rodriguez D. Atypical clinical and radiological
course of a patient with Canavan disease. Metab Brain Dis. 2016;31:475–9.
11. Gowda VK, Bhat MD, Srinivasan VM, Prasad C, Benakappa A, Faruq M. A case
of Canavan disease with microcephaly. Brain Dev. 2016;38:759–62.
12. Zano S, Wijayasinghe YS, Malik R, Smith J, Viola RE. Relationship between
enzyme properties and disease progression in Canavan disease. J Inherit
Metab Dis. 2013;36:1–6.
13. Tallan HH. Studies on the distribution of NAA in brain. J Biol Chem.
1957;224:41–5.
14. Kaul R, Gao GP, Balamurugan K, Matalon R. Cloning of the human
aspartoacylase cDNA and a common missense mutation in Canavan
disease. Nat Genet. 1993;5:118–23.
15. Bhakoo KK, Craig TJ, Styles P. Developmental and regional distribution of
aspartoacylase in rat brain tissue. J Neurochem. 2001;79:211–20.
16. Baslow MH, Guilfoyle DN. Canavan disease, a rare early-onset human
spongiform leukodystrophy: insights into its genesis and possible clinical
interventions. Biochimie. 2013;95:946–56.
17. Towfighi J, Friedman Z, Maisels MJ. Spongy degeneration of the central
nervous system (van Bogaert–Bertrand type?) in a newborn infant. Acta
Neuropathol (Berl). 1977;37:267–70.
18. Harding BN, Surtees R. Metabolic and neurodegenerative diseases of
childhood. In: Graham DI, Lantos PL, editors. Greenfield’s neuropathology,
vol. 1. 7th ed. London: Arnold Publishers; 2002. p. 485–517.
19. Leite CC, Reed UC, Otaduy MC, Lacerda MT, Costa MO, Ferreira LG, Carvalho
MS, Resende MB, Marie SK, Cerri GG. Congenital muscular dystrophy with
merosin deficiency: 1H MR spectroscopy and diffusion-weighted MR
imaging. Radiology. 2005;235:190–6.
20. Roscoe RB, Elliott C, Zarros A, Baillie GS. Non-genetic therapeutic
approaches to Canavan disease. J Neurol Sci. 2016;366:116–24.
21. McPhee SW, Francis J, Janson CG, Serikawa T, Hyland K, Ong EO, Raghavan
SS, Freese A, Leone P. Effects of AAV-2-mediated aspartoacylase gene
transfer in the tremor rat model of Canavan disease. Brain Res Mol Brain
Res. 2005;135:112–21.
22. Leone P, Shera D, McPhee SW, Francis JS, Kolodny EH, Bilaniuk LT, Wang DJ,
Assadi M, Goldfarb O, Goldman HW, Freese A, Young D, During MJ,
Samulski RJ, Janson CG. Long-term follow-up after gene therapy for
canavan disease. Sci Transl Med. 2012;4:165ra163.
23. Assadi M, Janson C, Wang DJ, Goldfarb O, Suri N, Bilaniuk L, Leone P.
Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in
Canavan disease. Eur J Paediatr Neurol. 2010;14:354–9.
24. Schaefer PW, Grant PE, Gonzalez RG. Diffusion-weighted MR imaging of the
brain. Radiology. 2000;217:331–45.
25. Janson CG, McPhee SW, Francis J, Shera D, Assadi M, Freese A, Hurh P,
Haselgrove J, Wang DJ, Bilaniuk L, Leone P. Natural history of Canavan
disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and
diffusion-weighted MRI. Neuropediatrics. 2006;37(4):209–21.
Merrill et al. Orphanet Journal of Rare Diseases  (2016) 11:169 Page 4 of 4
